MX2020003668A - Tratamiento de la enfermedad mediada por cml. - Google Patents

Tratamiento de la enfermedad mediada por cml.

Info

Publication number
MX2020003668A
MX2020003668A MX2020003668A MX2020003668A MX2020003668A MX 2020003668 A MX2020003668 A MX 2020003668A MX 2020003668 A MX2020003668 A MX 2020003668A MX 2020003668 A MX2020003668 A MX 2020003668A MX 2020003668 A MX2020003668 A MX 2020003668A
Authority
MX
Mexico
Prior art keywords
smc
treatment
mediated disease
prophylaxis
dysfunction
Prior art date
Application number
MX2020003668A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Wei Wen Lim
Benjamin Wei Ming Ng
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of MX2020003668A publication Critical patent/MX2020003668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

El diagnostico, el tratamiento y la profilaxis de enfermedades y afecciones asociadas con la disfunción de las células musculares lisas (CML) se proporcionan a través de la inhibición de la señalización mediada por IL-11.
MX2020003668A 2017-10-12 2018-10-12 Tratamiento de la enfermedad mediada por cml. MX2020003668A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1716733.9A GB201716733D0 (en) 2017-10-12 2017-10-12 Treatment of SMC mediated disease
PCT/EP2018/077940 WO2019073057A1 (en) 2017-10-12 2018-10-12 TREATMENT OF SMC MEDIATED DISEASE

Publications (1)

Publication Number Publication Date
MX2020003668A true MX2020003668A (es) 2020-08-20

Family

ID=60419332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003668A MX2020003668A (es) 2017-10-12 2018-10-12 Tratamiento de la enfermedad mediada por cml.

Country Status (14)

Country Link
US (2) US11780898B2 (es)
EP (1) EP3694876A1 (es)
JP (2) JP7704526B2 (es)
KR (1) KR102801430B1 (es)
CN (1) CN111655724A (es)
AU (1) AU2018347676B2 (es)
BR (1) BR112020007139A2 (es)
CA (1) CA3077368A1 (es)
CL (1) CL2020000966A1 (es)
EA (1) EA202090691A1 (es)
GB (1) GB201716733D0 (es)
MX (1) MX2020003668A (es)
PH (1) PH12020550255A1 (es)
WO (1) WO2019073057A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
US20200397816A1 (en) * 2019-06-24 2020-12-24 The Trustees Of Indiana University Methods to treat inflammatory and smooth muscle cell proliferation disorders
CA3211686A1 (en) * 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN116983413A (zh) * 2023-08-04 2023-11-03 中国医学科学院阜外医院 Plekhh2在肺动脉高压诊断和治疗方面的应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
US8361966B2 (en) 2006-10-27 2013-01-29 Osaka University Use of interleukin-11 as therapeutic agent for heart disease
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
KR102489953B1 (ko) 2013-02-07 2023-01-20 씨에스엘 리미티드 Il-11r 결합 단백질 및 이의 용도
WO2017049349A1 (en) 2015-09-25 2017-03-30 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment and prophylaxis
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
CA3045871A1 (en) * 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
EP3399398B1 (en) * 2017-05-02 2022-04-13 Nokia Technologies Oy An apparatus and associated methods for presentation of spatial audio
IL270321B2 (en) * 2017-05-05 2025-02-01 Huvepharma Modified sugars with anti-inflammatory activity
GB201809699D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
AU2018347676B2 (en) 2025-03-06
JP7704526B2 (ja) 2025-07-08
EP3694876A1 (en) 2020-08-19
WO2019073057A1 (en) 2019-04-18
KR20200093533A (ko) 2020-08-05
US11780898B2 (en) 2023-10-10
JP7704806B2 (ja) 2025-07-08
EA202090691A1 (ru) 2020-12-07
US20240141004A1 (en) 2024-05-02
PH12020550255A1 (en) 2020-12-07
CN111655724A (zh) 2020-09-11
JP2020536921A (ja) 2020-12-17
GB201716733D0 (en) 2017-11-29
CL2020000966A1 (es) 2021-02-26
JP2023113725A (ja) 2023-08-16
KR102801430B1 (ko) 2025-04-25
US20190241637A1 (en) 2019-08-08
BR112020007139A2 (pt) 2020-10-20
CA3077368A1 (en) 2019-04-18
AU2018347676A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
CL2020000966A1 (es) Tratamiento de enfermedad mediada por smc
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
UY37360A (es) Nucleósidos sustituidos, nucleótidos y análogos de estos
CO2020009106A2 (es) Derivados de tiofeno no condensados y sus usos
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
CL2017002223A1 (es) Métodos para el tratamiento de trastornos del movimiento involuntario anormal
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
NZ727392A (en) Methods of preparing substituted nucleotide analogs
MX386471B (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos
PH12017500747B1 (en) Heterocyclic compound
CL2021000007A1 (es) Tiofeno carboxamida sustituida y analogos como agentes antibacterianos
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
MX392523B (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
EP3481425A4 (en) Human Enzyme Mediated Depletion of Cystine to Treat Patients with Cystinuria
MX376080B (es) Moduladores del canal de potasio
PH12019502332A1 (en) Treatment of a bacterial vaginal infection
MX2020010667A (es) Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.